These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27106017)

  • 21. Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Tringale KR; Carroll KT; Zakeri K; Sacco AG; Barnachea L; Murphy JD
    J Natl Cancer Inst; 2018 May; 110(5):479-485. PubMed ID: 29126314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?
    Phippen NT; Leath CA; Miller CR; Lowery WJ; Havrilesky LJ; Barnett JC
    Gynecol Oncol; 2013 Aug; 130(2):317-22. PubMed ID: 23707667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost.
    Patnaik A; Doyle C; Oza AM
    Anticancer Drugs; 1998 Nov; 9(10):869-78. PubMed ID: 9890698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
    Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
    Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
    Narita Y; Matsushima Y; Shiroiwa T; Chiba K; Nakanishi Y; Kurokawa T; Urushihara H
    Lung Cancer; 2015 Oct; 90(1):71-7. PubMed ID: 26259876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain.
    Ojeda B; de Sande LM; Casado A; Merino P; Casado MA
    Br J Cancer; 2003 Sep; 89(6):1002-7. PubMed ID: 12966416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is centralization of ovarian cancer care warranted? A cost-effectiveness analysis.
    Greving JP; Vernooij F; Heintz AP; van der Graaf Y; Buskens E
    Gynecol Oncol; 2009 Apr; 113(1):68-74. PubMed ID: 19176236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma.
    Fedders M; Hartmann M; Schneider A; Kath R; Camara O; Oelschläger H
    J Cancer Res Clin Oncol; 2007 Sep; 133(9):619-25. PubMed ID: 17458562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can we maximize both value and quality in gynecologic cancer care? A work in progress.
    Havrilesky LJ; Fountain C
    Am Soc Clin Oncol Educ Book; 2014; ():e268-75. PubMed ID: 24857112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer.
    Dalton HJ; Yu X; Hu L; Kapp DS; Benjamin I; Monk BJ; Chan JK
    Gynecol Oncol; 2012 Feb; 124(2):199-204. PubMed ID: 22055763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer.
    Poonawalla IB; Lairson DR; Chan W; Piller LB; Du XL
    Value Health; 2015 Jun; 18(4):387-95. PubMed ID: 26091592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
    Lopes G; Glück S; Avancha K; Montero AJ
    Breast Cancer Res Treat; 2013 Jan; 137(1):187-93. PubMed ID: 23143283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer.
    Lobo JM; Trifiletti DM; Sturz VN; Dicker AP; Buerki C; Davicioni E; Cooperberg MR; Karnes RJ; Jenkins RB; Den RB; Showalter TN
    Clin Genitourin Cancer; 2017 Jun; 15(3):e299-e309. PubMed ID: 28089723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
    Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
    J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.
    Hinde S; Epstein D; Cook A; Embleton A; Perren T; Sculpher M
    Value Health; 2016 Jun; 19(4):431-9. PubMed ID: 27325335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
    Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
    Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation.
    Staropoli N; Ciliberto D; Chiellino S; Caglioti F; Giudice TD; Gualtieri S; Salvino A; Strangio A; Botta C; Pignata S; Tassone P; Tagliaferri P
    Oncotarget; 2016 Dec; 7(50):82741-82756. PubMed ID: 27764790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resource implications of palliative chemotherapy for ovarian cancer.
    Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
    J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.